Lexeo Q1 net loss $21.7M; cash $195.1M after $95M PIPE; pipeline milestones on track

Lexeo Therapeutics, Inc.

2024-Q1 EPS reported -$0.77

Q1 2024 net loss $21.7M ($0.77/share) vs $18.7M ($11.58/share) in Q1 2023.
Cash and equivalents $195.1M at March 31, 2024, after $95M PIPE; runway into 2027.
LX2006 (FA cardiomyopathy) granted FDA Fast Track; interim readout mid-2024.
LX2020 (PKP2-ACM) Phase 1/2 trial recruiting; Cohort 1 data update expected 2H 2024.
LX1001 (APOE4 Alzheimer's) all-cohort interim data expected 2H 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Lexeo Therapeutics, Inc. reported first quarter 2024 results: net income $21.7 million or $0.77 per share (basic and diluted), EPS $0.77 per share (basic and diluted).

Period: first quarter 2024
Net income: $21.7 million or $0.77 per share (basic and diluted)
EPS: $0.77 per share (basic and diluted)
Result: reported results

Exact text from the filing

Net loss was $21.7 million or $0.77 per share (basic and diluted) for the three months ended March 31, 2024

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Lexeo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056260

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.